{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

World MS Day latest: more than 50 per cent of MSIF members sign up

Has your MS society signed up to participate in the first ever World MS Day on Wednesday 27 May 2009?

read more

back to top

Profile of the Month : January 2009

Henri Goethals

Country: Belgium
Age: 62
Type of MS: Progressive MS
Year of Diagnosis: 1979

My attitude towards the disease has evolved considerably. In the beginning, nothing was stable or predictable, and everything was frightening. Now that the disease has taken a quieter course, life has become easier.

Deutsch English Espanol Francais Italiano Русский

read more

back to top

Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis

The authors studied a protein in the blood in the animal model of MS and found that it was a good marker of damage to nerve fibres in the brain. They suggest it may be helpful to assess the effect of neuroprotective therapies in the future.

authors: Gresle MM, Shaw G, Jarrott B, Alexandrou EN, Friedhuber A, Kilpatrick TJ, Butzkueven H

source: Clin. Immunol. 2008 Oct 20

read more

Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging

In this preliminary study, the authors used MRI techniques to investigate the effects of fluoxetine, an antidepressant medication, on preventing damage to brain cells in people with MS. They found that it may be neuroprotective although further, larger studies are needed.

authors: Sijens PE, Mostert JP, Irwan R, Potze JH, Oudkerk M, De Keyser J

source: Psychiatry Res. 2008 Dec 30;164(3):274-82.

read more

Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis

The authors studied the effects of combining two experimental treatments in the animal model of MS. They found that they may be neuroprotective and even promote repair of the nervous system.

authors: Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK

source: Glia. 2009 Jan 15;57(2):182-93.

read more

Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury

This study showed that specific components of the immune system contribute to inflammation and tissue injury in people with MS, and therefore provide a potential target for new treatments.

authors: Serafini B, Magliozzi R, Rosicarelli B, Reynolds R, Zheng TS, Aloisi F

source: J Neuropathol Exp Neurol. 2008 Dec;67(12):1137-48.

read more

Maternal smoking during pregnancy and multiple sclerosis amongst offspring

The cause of MS is not known but many factors have been implicated including environmental factors. The authors found that maternal smoking during pregnancy was not associated with MS in their children.

authors: Montgomery SM, Bahmanyar S, Hillert J, Ekbom A, Olsson T

source: Eur J Neurol. 2008 Dec;15(12):1395-9.

read more

Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis

This interesting study is the first report of an association between abnormalities of the veins of the central nervous system with the occurrence of MS. More work is required to determine the significance of this observation.

authors: Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall'ara S, Bartolomei I, Salvi F

source: J Neurol Neurosurg Psychiatry. 2008 Dec 5. [Epub ahead of print]

read more

back to top

Oral FTY720 (Fingolimod) reduced relapse rate more effectively than Avonex in initial results of one-year study in relapsing-remitting MS

source: US National MS Society

Initial results of a global study involving people with relapsing-remitting MS have been released.

read more

US think tank examines how to turn more lab discoveries into new therapies for progressive MS

source: US National MS Society

The US National MS Society (NMSS) organised a think tank in collaboration with the Harvard NeuroDiscovery Center to examine how to deliver new MS therapies.

read more

back to top

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

 Click here to learn more about the work of the Making Connections sponsor.